

Skin Cancer Phase I Clinical Trial Portfolio

Study Number	Disease Status	Slot Availability	Study Title	Cohorts/Tumor Types	Basic Eligibility
BMS CA027-002 (IL8)	Disease Specific	No Slot Request Required	A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers	Part 1B Dose Randomization - NSCLC, RCC, Melanoma	Disease Specific
Infinity IPI-549 (PI3K)	Disease Specific	Open and Enrolling	A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination with Nivolumab in Subjects with Advanced Solid Tumors	Expansion: NSCLC, melanoma, human papillomavirus (HPV) positive or HPV negative SCCHN; TNBC, ACC, mesothelioma, Urothelial	Disease Specific
Moderna mRNA-4157	Part Specific	Slots Strictly Allocated - Must Request Prior	A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors	Part A and Part B: NSCLC, SCLC, Melanoma, Bladder Urothelial Carcinoma, HPV(-) HNSCC, MSI-H Tumors, TMB-H Tumors	Part A: Patients must be willing to undergo apheresis procedure Part B: Patients must be willing to undergo biopsy
Regeneron R3767-ONC-1613	Disease Specific	Open and Enrolling	A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies	Expansion: Cohort 3 & 4 (I-O Naïve and experienced RCC), Cohort 6 Melanoma (I-O Naïve), Cohort 11&12 H&N SCC (I-O Naïve and experienced), Cohort 13 Cutaneous Squamous Cell (I-O experienced)	Disease Specific
Tesaro 4020-01-001	Disease Specific	Open and Enrolling	A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors	Pt 1e NSCLC and Melanoma. For Pt 2 Stage 1 Cohort B4 NSCLC	Disease Specific